Research analysts at StockNews.com began coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Get Free Report) in a research note issued to investors on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock.
Bellerophon Therapeutics Price Performance
BLPH stock opened at $0.04 on Tuesday. The business’s fifty day moving average is $0.05 and its 200-day moving average is $0.05. The company has a market cap of $428,155.00, a P/E ratio of -0.04 and a beta of 0.73. Bellerophon Therapeutics has a twelve month low of $0.03 and a twelve month high of $0.52.
Bellerophon Therapeutics Company Profile
Read More
- Five stocks we like better than Bellerophon Therapeutics
- There Are Different Types of Stock To Invest In
- Target Hits the Mark: Q2 Earnings Exceed Expectations
- Industrial Products Stocks Investing
- Is Tesla’s Rebound Just Starting? Why You Should Consider Buying
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Stanley Druckenmiller’s Latest Bet: MELI—Should You Follow Suit?
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.